



Newsletter from Emotra AB (publ)  
Göteborg, March 3, 2020

## Emotra will be participating in the Mangold Insight investor day

**This March, Emotra AB (“Emotra”) will be presenting the Company as well as our present situation, goals and strategy to create a new market for EDOR test in the psychiatric care sector. For more information about dates, locations, and the opportunity to meet our representatives and ask questions, see below.**

If you are interested in Emotra and want to learn more about the Company and our future opportunities, don't miss the opportunity to meet us at one of the following events in Sweden. Here is an overview with information about each event:

In Göteborg, at 2.45 pm on Wednesday, March 4, Emotra will be participating in the Life Science day. More information and event registration: <http://www.lifesciencedagen.se/anmaumllan.html>

In Stockholm, at 3 pm on Thursday, March 5, Emotra will be participating in the Mangold Insight investor day. This event will also be broadcast via their web site. Register at: [investerarlag@mangold.se](mailto:investerarlag@mangold.se)

In Malmö, at 1 pm on Tuesday, March 10, Emotra will be participating in an investor event at Mangold's office in Hamngatan 4. Register at: [emissionstjanster@mangold.se](mailto:emissionstjanster@mangold.se)

In Stockholm, on Monday, March 16, Emotra will be participating in Aktiedagen, which is organised by the Swedish Shareholders' Association. Emotra's presentation is at 8 pm. You can find more information about Aktiedagen here: <https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-16-mars>

Several of these events will be streamed online, so you can catch the presentation on your computer if you can't be there in person.

Welcome!

**For further information about the Company, please contact:** Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR<sup>®</sup>, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca Bio Venture-Hub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden.  
Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)